Search results
The Lancet reportedly pays for peer review "sometimes". Reviewers for journals published by the American Economic Association earn $100 for each "timely" review. Zentralblatt MATH (zbMATH) pays 2.56 EUR per review, although this is for post-publication reviews that are then published.
10 gru 2020 · The Oxford/AstraZeneca vaccine this week became the first major COVID vaccine candidate to have efficacy results from phase 3 trials published in a peer-reviewed journal. The vaccine,...
8 gru 2020 · The Oxford/AstraZeneca Covid vaccine is safe and effective, giving good protection, researchers have confirmed in The Lancet, external journal. Most in the study were younger than 55, but the...
22 lut 2021 · COV002 is a single-blinded, multi-centre, randomised, controlled Phase II/III trial assessing the safety, efficacy and immunogenicity of AstraZeneca’s COVID-19 vaccine in 12,390 participants in the UK.
8 gru 2020 · We report on the first clinical efficacy results of ChAdOx1 nCoV-19 in a pooled analysis of phase 2/3 trials in the UK and Brazil, and safety data from more than 20 000 participants enrolled across four clinical trials in the UK, Brazil, and South Africa.
Find a clinical trial. Sponsored by AstraZeneca or a member of the AstraZeneca Group of Companies. Search by Medical Condition or Trial Identifier. Search by Location. Distance. Search only trials that are recruiting or upcoming trials. Search clinical trial. For a more refined search use: Advanced search.
We identified 100 published peer-reviewed articles relevant to the Oxford–AstraZeneca vaccine or the ChAdOx technology (online supplemental files 1 and 2). Publication dates ranged from January 2002 to November 2020.
